SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:oru-3762"
 

Sökning: onr:"swepub:oai:DiVA.org:oru-3762" > Erythropoietin and ...

Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome

Jädersten, Martin (författare)
Malcovati, Luca (författare)
Dybedal, Ingunn (författare)
visa fler...
Della Porta, Matteo Giovanni (författare)
Invernizzi, Rosangela (författare)
Montgomery, Scott M., (författare)
Örebro universitet, Hälsoakademin
Pascutto, Cristiana (författare)
Porwit, Anna (författare)
Cazzola, Mario (författare)
Hellström-Lindberg, Eva (författare)
visa färre...
2008
Engelska.
Ingår i: Journal of Clinical Oncology. - New York, N.Y. : Grune & Stratton. - 0732-183X .- 1527-7755. ; 26:21, s. 3607-3613
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • <p><strong>Purpose</strong> To assess the effect of erythropoietin (EPO) plus granulocyte-colony stimulating factor (G-CSF) treatment on survival and leukemic transformation in myelodysplastic syndrome (MDS).</p> <p><strong>Patients and Methods</strong> We compared the long-term outcome of patients with MDS treated with EPO plus G-CSF (n = 121) with untreated patients (n = 237) with MDS using multivariate Cox regression with delayed entry, for the first time adjusting for all major prognostic variables (WHO classification, karyotype, cytopenias, level of transfusion-need, age, and sex).</p> <p><strong>Results</strong> The erythroid response rate to EPO plus G-CSF was 39%, and the median response duration 23 months (range, 3 to 116+). In the multivariate analysis, treatment was associated with improved overall survival (hazard ratio, 0.61; 95% CI, 0.44 to 0.83; <em>P</em> = .002). Interestingly, this positive association was primarily observed in patients requiring fewer than 2 units of RBCs per month. Treatment was not linked to the rate of acute myeloid leukemia in any defined subgroup, including patients with an increase of marrow blasts or an unfavorable karyotype.</p> <p><strong>Conclusion</strong> The inherent risk of leukemic evolution in MDS makes the current investigation highly relevant, in light of the recent reports of potential negative effects of EPO treatment on outcome in patients with cancer. We conclude that treatment of anemia in MDS with EPO plus G-CSF may have a positive impact on outcome in patients with no or low transfusion need, while not affecting the risk of leukemic transformation.</p>

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  (hsv//swe)
MEDICAL AND HEALTH SCIENCES  (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kirurgi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Surgery (hsv//eng)

Nyckelord

Aged
Anemia/drug therapy/etiology
Blood Transfusion
Cell Transformation; Neoplastic/*drug effects
Clinical Trials; Phase II as Topic
Erythropoietin/*therapeutic use
Female
Granulocyte-Macrophage Colony-Stimulating Factor/*therapeutic use
Humans
Kaplan-Meiers Estimate
Leukemia; Myeloid; Acute/epidemiology
Male
Middle Aged
Myelodysplastic Syndromes/complications/*drug therapy/mortality
Precancerous Conditions/*drug therapy
MEDICINE
MEDICIN
MEDICINE Surgery Oncology
MEDICIN Kirurgi Onkologi
MEDICINE Surgery
MEDICIN Kirurgi
Onkologi
Oncology

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)
ref (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy